307538-42-7 Usage
Description
SMER28 (CAS 307538-42-7) Induces autophagy via an mTOR-independent pathway. Enhances clearance of ?-amyloid protein in cell lines and primary neuronal culture models.1-3? May be a useful lead compound for the development of new therapeutics for neurodegenerative diseases.4?Induces the release of articular cartilage vesicles from healthy articular chondrocytes in a dose- and time-dependent manner.5? Promotes reprogramming of fibroblasts to neural stem-like cells.6?Cell permeable.
Uses
Different sources of media describe the Uses of 307538-42-7 differently. You can refer to the following data:
1. SMER 28 is a positive regulator of autophagy in a mechanism independent from the mTOR pathway. SMER 28 increases autophagosome synthesis and enhances clearance of model autophagy substrates such as A5
3T α-synuclein associated with Huntington's disease.
2. SMER 28 is a positive regulator of autophagy in a mechanism independent from the mTOR pathway. SMER 28 increases autophagosome synthesis and enhances clearance of model autophagy substrates such as A53T α-synuclein associated with Huntington''s disease.
3. SMER28 may be used in mTOR-mediated signaling studies.
Biochem/physiol Actions
SMER28 is a small molecule modulator of mammalian autophagy; enhances A53T alpha-synuclein clearance in PC-12 cells independent of rapamycin treatment; appears to act independent of the mTOR pathway, but combined treatment with saturating rapamycin concentration enhances the effect of either compound alone on A53T alpha-synuclein clearance; autophagy inducers may prove useful in the treatment of neurodegenerative and infectious diseases and cancer.
in vitro
smer 28 independently induced autophagy of rapamycin in mammalian cells, enhancing the clearance of autophagy substrates such as a53t a-synuclein and mutant huntingtin, which were associated with huntington’s and parkinson’s disease. smer 28, which seemed to act either independently or downstream of the rapamycin target, was found to attenuate the mutant huntingtin-fragment toxicity in huntington’s disease cells [1].
in vivo
previous study confirmed that the reduction of egfp-hdq74 aggregation occured through autophagy using autophagy-competent mouse embryonic fibroblasts (mefs) (atg5+/+). egfp-hdq74 aggregation was increased significantly in untreated atg5-/- (autophagy-deficient) cells when compared with untreated atg5+/+ cells. smer 28 reduced egfp-hdq74 aggregation in atg5+/+ cells significantly, but not in atg5-/- cells). therefore, smer 28 could only reduce mutant huntingtin aggregation in autophagy-competent cells [1].
References
1) Tian et al. (2011), A small-molecule enhancer of autophagy decreases levels of Abeta and APP-CTF via Atg5-dependent autophagy pathway; FASEB J., 25 1934
2) Tian et al. (2014), The convergence of endosomal and autophagosomal pathways; implications for APP-CTF degradation; Autophagy, 10 694
3) Shen et al. (2011), Novel cell- and tissue-based assays for detecting misfolded and aggregated protein accumulation within aggresomes and inclusion bodies; Cell Biochem. Biophys., 60 173
4) Renna et al. (2010), Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases; J. Biol. Chem., 285 11061
5) Rosenthal et al. (2015), Autophagy modulates articular cartilage vesicle formation in primary articular chondrocytes; J. Biol. Chem., 290 13028
6) Zhang et al. (2016), Pharmacological Reprogramming of Fibroblasts into Neural Stem Cells by Signaling-Directed Transcriptional Activation; Cell Stem Cell., 18 653
Check Digit Verification of cas no
The CAS Registry Mumber 307538-42-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,7,5,3 and 8 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 307538-42:
(8*3)+(7*0)+(6*7)+(5*5)+(4*3)+(3*8)+(2*4)+(1*2)=137
137 % 10 = 7
So 307538-42-7 is a valid CAS Registry Number.
307538-42-7Relevant articles and documents
Potent inhibitors of Huntingtin protein aggregation in a cell-based assay
Rinderspacher, Alison,Cremona, Maria Laura,Liu, Yidong,Deng, Shi-Xian,Xie, Yuli,Gong, Gangli,Aulner, Nathalie,Toebben, Udo,Myers, Katherine,Chung, Caty,Andersen, Monique,Vidovic, Dusica,Schuerer, Stephan,Branden, Lars,Yamamoto, Ai,Landry, Donald W.
experimental part, p. 1715 - 1717 (2009/12/03)
A quinazoline that decreases polyglutamine aggregate burden in a cell-based assay was identified from a high-throughput screen of a chemical-compound library, provided by the NIH Molecular Libraries Small Molecule Repository (MLSMR). A structure and activ